We tested infectious human immunodeficiency virus type 1 (HIV-1), noninfectious but conformationally authentic inactivated whole HIV-1 virions, and purified gp120 for the ability to induce depletion of CD4 ؉ T cells in human lymphoid tissues ex vivo. Infectious CXCR4-tropic HIV-1, but not matched inactivated virions or gp120, mediated CD4
؉ T-cell depletion, consistent with mechanisms requiring productive infection.
The critical events in human immunodeficiency virus (HIV) disease occur in human lymphoid tissue, where HIV infection is associated with a cumulatively massive depletion of CD4 ϩ T lymphocytes. Since HIV was first cultured, it has been known that lytic infection can directly kill infected cells in vitro. Other killing mechanisms, both direct and indirect, have also been proposed (1, 4, 5, 7, 11-14, 16, 18-23, 26-30) . It remains controversial, however, whether and to what extent uninfected cells are killed. It has been proposed that some indirect cell killing may be mediated by interactions between bystander cells and HIV surface molecules (2, 6, 15, 17, 24, 26, 31) . We combined a unique ex vivo culture system and a novel means of inactivating HIV type 1 (HIV-1) to test whether depletion of CD4 ϩ T cells in human lymphoid tissue depends on viral replication or can be triggered by virions or viral proteins, even in the absence of productive infection.
We have shown previously that blocks of human lymphoid tissue cultured ex vivo support productive infection with HIV-1 without exogenous stimulation (8) (9) (10) . In this system, infection with T-cell/CXCR4-tropic (X4) (3) but not with macrophage/ CCR5-tropic (R5) (3) HIV-1 isolates results in CD4 ϩ T-lymphocyte depletion (9). We recently described inactivation of the infectivity of HIV-1 by a novel method which preserves the conformational and functional integrity of virion surface proteins (25) . Treatment of virions with 2,2Ј-dithiodipyridine (aldrithiol-2 [AT-2]; Sigma Chemical Co., St. Louis, Mo.) (100 mM for 1 h; 37°C) inactivates virions by covalent disruption of zinc fingers in the viral nucleocapsid protein (25) , required in multiple steps of the viral life cycle. Afterwards, AT-2 is diluted 27,000-fold from treated virions with a centrifugal concentrator with a 500-kDa-cutoff membrane (Amicon, Beverly, Mass.). Experiments with virus-free culture medium spiked with AT-2 showed that the residual concentration of AT-2 did not mediate detectable effects on histoculture cell viability, HIV replication, or B-cell function (as assayed by trypan blue exclusion, HIV p24 enzyme-linked immunosorbent assay [ELISA], or total immunoglobulin G ELISA, respectively.)
We compared X4-tropic infectious virus, AT-2 inactivated virions, and purified gp120 for the ability to deplete CD4 demonstrated both by titrations with peripheral blood mononuclear cells, confirming an earlier report (25) , and by the finding that tonsil tissues inoculated with inactivated virus did not secrete p24 into culture supernatants (measured by ELISA [AIDS Vaccine Program]).
Tonsil cultures were inoculated with either live or inactivated LAV.04 or LAI (IIIB). Infectious virus was applied to 2-mm blocks of human tonsil tissue as a single dose on day 1 of culture, with approximately 400 50% tissue culture infectious doses per block, as described previously (8) . The kinetics of HIV replication in this culture system are shown in Fig. 1 . Inactivated virus was applied to cultures by either of two protocols. In one, inactivated virus was applied on day 1 and every third day in amounts chosen to approximate the typical growth kinetics for LAV.04 (Fig. 1) . Alternatively, inactivated virus was maintained at a constant supernatant concentration (5 to 20 ng of p24/ml) from day 1 of culture ( Fig. 1) . Results were comparable for the two protocols and for studies using both LAV.04 and LAI (IIIB) viruses. CD4 ϩ T-cell depletion was assessed by the CD4 ϩ /CD8 ϩ ratio among T lymphocytes, determined by flow cytometry of cells recovered mechanically from tissue blocks (9) . Infection with untreated virus resulted in CD4 ϩ T-cell depletion greater than 90% relative to uninfected controls (Fig. 2) , whereas no depletion (95% confidence) was observed in cultures exposed to AT-2-treated virus. Similar results were obtained even when inactivated virus was added at a 100-fold excess over peak concentrations in matched infected cultures (data not shown).
Results with gp120 were similar to those obtained with inactivated virus. In these experiments, gp120 was incubated with tissues at a concentration of 8 pM, a level found in supernatants of typical infected cultures at peak virus replication. After 15 days of continuous exposure to gp120 from X4 strain LAV.04, no significant CD4 ϩ T-cell depletion was seen (Fig.  2) . Incubations with glycosylated and nonglycosylated gp120 from the X4 strain SF2 gave similar results. Moreover, no depletion was seen when gp120 was added to a background of live infection with the R5 virus isolate SF162, which itself does not deplete CD4 ϩ T cells (9) . Inactivation of HIV-1 by AT-2 results in noninfectious virus that is capable of authentic binding to and fusion with target cell membranes but incapable of initiating reverse transcription (25) . Such virions should be capable of mediating many of the interactions with cell membranes presumed to be responsible for indirect mechanisms of CD4 ϩ T-cell loss (2, 6, 7, 12, 27) . It is conceivable that indirect mechanisms of cell killing require concentrations of virus higher than those examined here and that such higher concentrations might occur in microenvirionments directly adjacent to productively infected cells. However, no depletion of CD4 ϩ T cells was observed, even with exposure to a 100-fold-increased concentration of inactivated virus, which simulated retention of the equivalent of 3 days of peak virus production entirely within the tissue. The absence of CD4 ϩ T-cell depletion under even these extreme conditions strongly implies that CD4 ϩ T-cell killing requires productive HIV infection in ex vivo tonsil histocultures and, by inference, in human lymphoid tissue in vivo.
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FIG. 2. Depletion of CD4
ϩ T lymphocytes in lymphoid tissue ex vivo. Shaded bars represent tissues exposed to infectious X4 isolate LAV.04 or LAI (IIIB). Open bars represent tissues exposed to inactivated virus or to gp120. Tissues were analyzed on day 15 of culture, and results are expressed as a percentage relative to uninfected controls from the same donors. Bars represent averages (Ϯ standard error of the mean) of data from three to eight experiments, each using tissue from different donors. Measurements in each experiment were based on pooling of 12 to 18 identically treated tissue blocks. ‫,ء‬ no significant difference from uninfected control (95% confidence); ‫,ءء‬ significant difference from uninfected control (P Ͻ 0.01).
